Chronic inflammation: Synergistic interactions of recruiting macrophages (TAMs) and eosinophils (EoS) with host mast cells (MCs) and tumorigenesis in CALTs. M-CSF, suitable biomarker for cancer diagnosis

Cancers

Volumn 6, Issue 1, 2014, Pages 297-322

  Khatami, Mahin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer biomarkers; Conjunctival associated lymphoid tissues (CALTS); Immune surveillance; Mast cells; Neurodegenerative and autoimmune diseases; Targeted therapies; Tumor associated macrophages (TAMs); Yin and yang of acute inflammation

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; COLONY STIMULATING FACTOR 1; HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; INTERLEUKIN 5; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

AGING; ANTIGEN PRESENTING CELL; CANCER DIAGNOSIS; CANCER PREVENTION; CARCINOGENESIS; CHRONIC DISEASE; CHRONIC INFLAMMATION; CONJUNCTIVA; CONJUNCTIVAL ASSOCIATED LYMPHOID TISSUE; DOWN REGULATION; EOSINOPHIL; EYE INFLAMMATION; GERMINAL CENTER; GOBLET CELL; HISTAMINE METABOLISM; HISTIOCYTE; HUMAN; HUMORAL IMMUNITY; IMMUNOSURVEILLANCE; LYMPHOID HYPERPLASIA; LYMPHOID TISSUE; MACROPHAGE ACTIVATION; MAST CELL; MAST CELL DEGRANULATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PROSTAGLANDIN SYNTHESIS; REVIEW; RISK ASSESSMENT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

EID: 84893362303     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6010297     Document Type: Review

References (104)

1. Ehrlich, P. Uber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 1909, 5, 273-290.
2. Burnet, M. Cancer; a biologic approach. I. The processes of control. Br. Med. J. 1957, 1, 779-786.
3. Khatami, M. Inflammation, Aging and Cancer: Friend or For? In Inflammation, Chronic Diseases and Cancer. Cell and Molecular Biology, Immunology and Clinical Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 3-30.
4. Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650-1659.
5. Aprahamian, T. Autoimmunity, atherosclerosis and apoptic cell clearance. In Inflammation, Chronic Diseases and Cancer. Cell and Molecular Biology, Immunology and Clinical Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 75-96.
6. Fischetti, F.; Tedesco, F. Cross-talk between the complement system and endothelial cells in physiologic conditions and vascular diseases. Autoimmunity 2006, 39, 417-428.
7. Culmsee, C.; Landshamer, S. Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr. Alzheimer Res. 2006, 3, 269-283.
8. Keibel, A.; Singh, V.; Sharma, M.C. Inflammation, microenvironment, and the immune system in cancer progression. Curr. Pharm. Des. 2009, 15, 1949-1955.
9. Davalos, A.R.; Coppe, J.P.; Campisi, J.; Desprez, P.Y. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010, 29, 273-283.
10. Hanson, A.; Gosemann, M.; Pruss, A.; Reiter, K.; Ruzickova, S.; Lipsky, P.E.; Domer, T. Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome. Arthritis Rheum. 2004, 50, 1897-1908.
11. Harrois, A.; Huet, O.; Duranteau, J. Alterations of mitochondrial function in sepsis and critical illness. Curr. Opin. Anesthesiol. 2009, 22, 143-149.
12. Barcante, J.M.P.; Barcante, T.A.; Peconick, A.P.; Pereira L.J.; Lima, W.S. Parasitic infections and inflammatory diseases. In Inflammation, Chronic Diseases and Cancer. Cell and Molecular Biology, Immunology and Clinical Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 205-218.
13. Serafin, W.E.; Austen, K.F. Mediators of immediate hypersensitivity reactions. N. Engl. J. Med. 1987, 317, 30-34.
14. Bischoff, S.C. Role of mast cells in allergic and non-allergic immune responses: Comparison of human and murine data. Nat. Rev. Immunol. 2007, 7, 93-104.
15. Arias, J.I.; Aller, M.A.; Arias, J. Cancer cell: Using inflammation to invade the host. Mol. Cancer 2007, 6, 29.
16. Eiró, N.; Vizoso, F.J. Inflammation and cancer. World J. Gastrointest. Surg. 2012, 27, 62-72.
17. Azim, H.; Azim, H.A., Jr. Targeting RANKL in breast cancer: Bone metastasis and beyond. Exp. Rev. Anticancer Ther. 2013, 13, 195-201.
18. Moore, M.M.; Chua, W.; Charles, K.A.; Clarke, S.J. Inflammation and cancer: Causes and consequences. Clin. Pharmacol. Ther. 2010, 87, 504-508.
19. Lu, W.; Lu, L.; Feng, Y.; Chen, J.; Li, Y.; Kong, X.; Chen, S.; Li, X.; Chen, Q.; Zhang, P. Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. Oncol. Lett. 2013, 5, 1519-1526.
20. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2005, 5, 953-964.
21. Akova, Y.A.; Gungar, S.G. Ocular involvement in Behcet's disease. In Inflammation, Chronic Diseases and Cancer. Cell and Molecular Biology, Immunology and Clinical Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 391-416.
22. Su, S.C.; Hua, K.F.; Lee, H.; Chao, L.K.; Tan, S.K; Yang, S.F.; Hsu, H.Y. LTA and LPS mediated activation of protein kinases in the regulation of inflammatory cytokines expression in macrophages. Clin. Chim. Acta 2006, 374, 106-115.
23. Issa, L.A. Biologic agents for inflammatory bowel disease: The current, the future and the controversy. In Inflammation, Chronic Diseases and Cancer. Cell and Molecular Biology, Immunology and Clinical Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 417-430.
24. Chen, C.-J.; Chin, J.E.; Ueda, K. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47, 381-389.
25. Mottet, C.; Uhlig, H.H.; Powrie, F. Cutting edge: Cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol. 2003, 170, 3939-3943.
26. Gukovskaya, A.S.; Gukovsky, I. Autophagy and pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303, G993-G1003.
27. Drayton, D.L.; Liao, S.; Mounzer, R.H.; Ruddle, N.H. Lymphoid organ development: From ontology to neogenesis. Nat. Immunol. 2006, 7, 344-353.
28. Harvey, B.P.; Quan, T.F.; Rudenga, B.J.; Roman, R.M.; Craft, J.; Mamula, M.J. Editing antigen presentation: Antigen transfer between B lymphocyte and macrophages mediated by Class A Scavenger receptors. J. Immunol. 2008, 181, 4043-4051.
29. Sriskandan, S.; Cohen, J. Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect. Dis. Clin. North Am. 1999, 13, 397-412.
30. Dranoff, G. Immune recognition and tumor protection. Curr. Opin. Immunol. 2002, 14, 161-164.
31. Davis, B.K.; Wen, H.; Ting, J.P. The inflammasome NLRs in immunity, inflammation and associated disease. Ann. Rev. Immunol. 2011, 29, 707-735.
32. Heinz, C.; Fanihagh, F.; Steuhl, K.P. Squamous cell carcinoma of the conjunctiva in patients with atopic eczema. Cornea 2003, 22, 135-137.
33. Jabaut, J.; Ckless, K. Inflammation, immunity and redox signaling. In Inflammation, Chronic Diseases and Cancer. Cell and Molecular Biology, Immunology and Clinical Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp.145-160.
34. Rubtsov, Y.P.; Rasmussen, J.P.; Chi, E.Y.; Fontenot, J.; Castelli, L.; Ye, X.; Treuting, P.; Siewe, L.; Roers, A.; Henderson, W.R., Jr.; Muller, W.; Rudensky, A.Y. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28, 546-558.
35. Khatami, M.; Donnelly, J.J.; John, T.; Rockey, J.H. Vernal conjunctivitis. Model studies in guinea pigs immunized topically with fluoresceinyl ovalbumin. Arch. Ophthalmol. 1984, 102, 1683-1688.
36. Khatami, M.; Donnelly, J.J.; Haldar, J.P.; Rockey, J.H. Massive follicular lymphoid hyperplasia in experimental chronic recurrent allergic conjunctivitis. Arch. Ophthalmol. 1989, 107, 433-438.
37. Khatami, M. Developmental phases of inflammation-induced massive lymphoid hyperplasia and extensive changes in epithelium in an experimental model of allergy. Implications for a direct link between inflammation and carcinogenesis. Am. J. Ther.2005, 12, 117-128.
38. Khatami, M. "Yin and Yang"in inflammation: Duality in innate immune cell function and tumorigenesis. Exp. Opin.Biol. Ther. 2008, 8, 1461-1472.
39. Khatami, M. Inflammation, aging and cancer: Tumoricidal vs tumorigenesis of immunity: A common denominator mapping chronic diseases. Cell Biochem. Biophys. 2009, 55, 55-79.
40. Khatami, M. Unresolved inflammation: "Immune tsunami"or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer. Exp. Opin. Biol. Ther. 2011, 11, 1419-1432.
41. Innocenti, F.; Cox, N.J.; Dolan, M.E. The use of genomic information to optimize cancer chemotherapy. Semin. Oncol. 2011, 38, 186-195.
42. Liu, F.S. Mechanisms of chemotherapeutic drug resistance in cancer therapy-A quick review. Taiwan. J. Obstet. Gynecol. 2009, 48, 239-244.
43. Karwacz, K.; Arce, F.; Bricogne, C.; Kochan, G.; Escors, D. PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. Oncoimmunology 2012, 1, 86-88.
44. Steele, C.W.; Jamieson, N.B.; Evans, T.R.; McKaym C.J.; Sansom, O.J.; Morton J.P.; Carter, C.R. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br. J. Cancer 2013, 108, 997-1003.
45. Khatami, M. Induction of conjunctival-associated lymphoid hyperplasia by antigen and tumor promoting agents: Targeting mediators of inflammatory responses as biomarkers for early detection of tumor/cancer. Special Conference Proceedings: The Biology and Genetics of Early Detection and Chemoprevention of Cancer, Am Assoc Cancer Research, Bal Harbour, FL, USA, 6-10 October 1999.
46. Mierke, C.T. Physical break-down of the classical view on cancer cell invasion and metastasis. Eur. J. Cell Biol. 2013, 92, 89-104.
47. Schumann, J. The impact of macrophage membrane lipid composition on innate immune response mechanisms. In Inflammation, Chronic Diseases and Cancer. Cell and Molecular Biology, Immunology and Clinical Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 31-52.
48. Khatami, M. (NCI) Standardizing Criteria on Cancer Biomarkers as Foundation of a Database: Creating a Common Language (Data Elements) for Cancer Biomarkers Tracking and Utilization for Professionals in Oncology Research, HHS Reference No. E-147-2005/0-Research Tool; Federal Register: Washington, DC, USA, 2005.
49. Gurish, F.; Boyce, J.A. Mast cells: Ontogeny, homing, and recruitment of a unique innate effector cell. J. Allerg. Clin. Immunol. 2006, 117, 1285-1291.
50. Carow, B.; Rottenberg, M.E. Suppressor of cytokine signalling": Molecules in infection and inflammation; In Inflammation, Chronic Diseases and Cancer. Cell and Molecular Biology, Immunology and Clinical Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 279-306.
51. Reichmann, N.T.; Gründling, A. Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Firmicutes. FEMS Microbiol. Lett. 2011, 319, 97-105.
52. Round, J.L.; Mazmanian, S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 2009, 9, 313-323.
53. Tam, S.Y.; Tsai, M.; Yamaguchi, M.; Yano, K.; Butterfield, J.H.; Galli, S.J. Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. Blood 1997, 90, 1807-1820.
54. Sansonetti, P.J. War and peace at mucosal surfaces. Nat. Rev. Immunol. 2004, 4, 953-964.
55. Goronzy, J.J.; Wevand, C.M. T cell development and receptor diversity during aging. Curr. Opin. Immunol. 2005, 17, 468-475.
56. Khatami, M. Unresolved inflammation and cancer: Loss of natural immune surveillance as the correct "target"for therapy! Seeing the "Elephant"in the light of logic. Cell Biochem. Biophys. 2012, 62, 501-509.
57. Khatami, M. Standardizing cancer biomarkers criteria: Data elements as a foundation for a database. Inflammatory mediator/M-CSF as model marker. Cell Biochem. Biophysics. 2007, 47, 187-198.
58. Gounaris, E.; Blatner, N.R.; Dennis, K.; Magnusson, F.; Gurish, M.F.; Storm, T.B.; Beckhove, P.; Gounari, F.; Khazaie, K. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 2009, 69, 5490-5497.
59. Theoharides, T.C.; Alysandratos, K.D.; Angelidou, A.; Delivanis, D.A.; Sismanopoulos, N.; Zhang, B.; Asadi, S.; Vasiadi, M.; Weng, Z.; Miniati, A.; Kalogeromitros, D. Mast cells and inflammation. Biochim. Biophys. Acta 2012, 1822, 21-33.
60. Gounaris, E.; Erdman, S.E.; Restanio, C.; Gurish, M.F.; Friend, D.S.; Lee, D.M.; Zhang, G.; Glickman, J.N.; Shin, K.; Rao, V.P., et al. Mast cells are an essential hematopoietic component for polyp development. Proc. Natl. Acad. Sci. USA 2007, 104, 19977-19982.
61. Kormelink, T.G.; Askenase, P.W.; Redegeld, F.A. Immunobiology of antigen-specific immunoglobulin free light chains in inflammatory diseases. Curr. Pharm. Design 2012, 18, 2278-2289.
62. Blank, U.; Rivera, J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol. 2004, 25, 266-273.
63. Siraganian, R.P. Mast cell signal transduction from the high-affinity IgE receptor. Curr. Opin. Immunol. 2003, 15, 639-646.
64. Kraft, S.; Kinet, J.P. New developments in Fc epsilonRI regulation, function and inhibition. Nat. Rev. Immunol. 2007, 7, 365-378.
65. Redegeld, F.A.; Nijkamp, F.P. Immunoglobulin free light chains and mast cells: Pivotal role in T-cell-mediated immune reactions? Trends Immunol. 2003, 24, 181-185.
66. Hamrah, P.; Hug, S.O.; Liu, Y.; Zhang, Q.; Dana, M.R. Corneal immunity is mediated by heterogenous population of antigen-presenting cells. J. Leukoc. Biol. 2003, 74, 172-178.
67. Stoecker, M.M.; Wang, E. Histiocytic/dendritic cell transformation of B-cell neoplasms: Pathologic evidence of lineage conversion in differentiated hematolymphoid malignancies. Arch. Pathol. Lab Med. 2013, 137, 865-870.
68. Rodriguez, L.L.; Schneider, I.C. Directed cell migration in multi-cue environments. Integr. Biol. Camb. 2013, 5, 1306-1323.
69. D'Amato, G.; Salzillo, A.; Piccolo, A.; D'Amato, M.; Liccardi, G. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma. Ther. Clin. Risk Manag. 2007, 3, 613-619.
70. Bienenstock, J.; Tomioka, M.; Matsuda, H.; Stead, R.H.; Quinonez, G.; Simon, G.T.; Coughlin, M.D.; Denburg, J.A. The role of mast cells in inflammatory processes: Evidence for nerve mast cell interactions. Int. Arch. Allergy Appl. Immunol. 1987, 82, 238-243.
71. Tal, M.; Liberman, R. Local injection of nerve growth factor (NGF) triggers degranulation of mast cells in rat paw. Neurosci. Lett. 1997, 221, 129-132.
72. Hotamisisligil, G.S. Inflammation and metabolic disorders. Nature 2006, 444, 860-867.
73. De Simone, R.; Alleva, E.; Tirassa, P.; Aloe, L. Nerve growth factor released into the bloodstream following intraspecific fighting induces mast cell degranulation in adult male mice. Brain Behav. Immun. 1990, 4, 74-81.
74. Allakhverdi, Z.; Comeau, M.R.; Jessup, H.K.; Yoon, B.P.; Breuer, A.; Chartier, S.; Paquette, N.; Ziegler, S.F.; Sarfati, M.; Delespesse, G. Thymic stromal lymphopoietin is released by human epithelial cell in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med. 2007, 19, 253-258.
75. Kumar, V. Innate immune system in sepsis immunopathogenesis and its modulation as future therapeutic approach. In Inflammatory Diseases; Immunopathology, Clinical and Pharmacological Bases; Khatami, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 57-82.
76. Matsuda, H.; Kawakita, K.; Kiso, Y.; Nakano, T.; Kitamura, Y. Substance P induces granulocyte infiltration through degranulation of mast cells. J. Immunol. 1989, 142, 927-931.
77. Khatami, M. Cyclooxygenase inhibitor Ketorolac or mast cell stabilizers: Immunological challenges in cancer therapy. Letters to the Editor. Clin. Cancer Res. 2005, 11, 1350-1352.
78. Ledford, H. Translational research: 4 ways to fix the clinical trial. Nature 2011, 477, 526-528.
79. Pathology of Incipient Neoplasia, 3rd ed.; Henson, D.E., Alborez-Saavedra, J., Eds.; Oxford: Oxford University Press: New York, NY, USA, 2001.
80. Gargalionis, A.N.; Piperi, C.; Adamopoulos, C.; Papavassiliou, A.G. Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. Int. J. Biochem. Cell Biol. 2012, 44, 1276-1289.
81. Di Virgilio, F. The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol. Rev. 2013, 65, 872-905.
82. Wakefield, L.M.; Hill, C.S. Beyond TGFß: Roles of other TGFβ superfamily members in cancer. Nat. Rev. Cancer 2013, 13, 328-341.
83. Ferrantini, M.; Capone, I.; Belardelli, F. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Rev. 2008, 19, 93-107.
84. Zack, T.R.; Schumacher, S.E.; Carter, S.L.; Cherniack, A.D.; Saksena, G.; Tabak, B.; Lawrence M.S.; Zhang, C.Z.; Wala, J.; Mermel, C.H., et al. Pan-cancer pattern of somatic copy number alteration. Nat. Genet. 2013, 45, 1134-1140.
85. Zanetti, M. Cell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells. Ann. NY Acad. Sci. 2013, 1284, 6-11.
86. Blatner, N.R.; Mulcahy, M.F.; Dennis, K.L.; Scholtens, D.; Bentrem, D.J.; Phillips, J.D.; Ham, S.; Sandall, B.P.; Khan, M.W.; Mahvi, D.M., et al. Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci. Transl. Med. 2012, 4, 164-159.
87. Khatami, M.; Donnelly, J.J.; Rockey, J.H. Induction and down-regulation of conjunctival type-1 hypersensitivity reactions in guinea pigs sensitized topically with fluoresceinyl ovalbumin. Ophthalmic Res. 1985, 17, 139-147.
88. Haldar, J.P.; Khatami, M.; Donnelly, J.J.; Rockey, J.H. Experimental allergic conjunctivitis: Production of different isotypes of antibody by conjunctival-associated lymphoid tissue in culture. Reg. Immunol. 1988, 1, 92-99.
89. Helleboid, L.; Khatami, M.; Wei, Z.-G.; Rockey, J.H. Histamine and prostacyclin: Primary and secondary release in allergic conjunctivitis. Invest. Ophthalmol. Vis. Sci. 1991, 32, 2281-2289.
90. Donnelly, J.J.; Taylor, J.R.; Young, E.; Khatami, M.; Lok, J.B.; Rockey, J.H. Experimental ocular onchocerciasis in cynomolgus monkeys. Invest. Ophthalmol. Vis. Sci. 1986, 27, 492-499.
91. Topalkara, A.; Ben-Arie-Weintrob, Y.; Ferry, J.A.; Foster, C.S. Conjunctival marginal zone B-cell lymphoma (MALT lymphoma) with amyloid and relapse in the stomach. Ocul. Immunol. Inflamm. 2007, 15, 347-350.
92. Choudry, H.A.; O'Malley, M.E.; Guo, Z.S.; Zeh, H.J.; Bartlett, D.L. Mucin as a therapeutic target in pseudomyxoma peritoneal. J. Surg. Oncol. 2012, 106, 911-917.
93. Mantovani, A.; Sica, A. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22, 231-237.
94. Ding, T.; Xu, J.; Wang, F.; Shi, M.; Zhang, Y.; Li, S.P.; Zheng, L. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Human Pathol. 2009, 40, 381-389.
95. Werno, C.; Menrad, H.; Weigert, A.; Dehne, N.; Goerdt, S.; Schledzewski, K.; Kzhyshkowska, J.; Brune, B. Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis 2010, 31, 1863-1872.
96. Capece, D.; Fischietti, M.; Verzella, D.; Gaggiano, A.; Cicciarelli, G.; Tessitore, A.; Zazzeroni, F.; Alesse, E. The inflammatory microenvironment in hepatocellular carcinoma: A pivotal role for tumor-associated macrophages. Biomed. Res. Int. 2013, 2013, 187-204.
97. Tataroǧlu, C.; Kargi, A.; Ozkal, S.; Eşrefoǧlu, N.; Akkoçlu, A. Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer 2004, 43, 47-54.
98. Zhou, J.; Ding, T.; Pan, W.; Zhu, L.Y.; Li, A.; Zheng, L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int. J. Cancer 2009, 125, 1640-1648.
99. Spear, P.; Barber, A.; Rynda-Apple, A.; Sentman, C.L. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J. Immunol. 2012, 188, 6389-6398.
100. Wang, R.; Ma, Z.; Wang, Y.; Cheng, Z.; Xu, H.; Li, W.; Wang, X. The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer. Gynecol. Oncol. 2010, 117, 460-466.
101. Bonde, A.K.; Tischler, V.; Kumar, S.; Soltermann, A.; Schwendener, R.A. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 2012, 12, 35.
102. Wilson, C.M.; Magnaudeix, A.; Yardin, C.; Terro, F. Autophagy dysfunction and its link to Alzheimer's disease and Type II diabetes mellitus. CNS Neurol. Disord. Drug Targets 2013, PMID:24059314.
103. Kondratskyi, A.; Yassine, M.; Kondratska, K.; Skryma, R.; Slomianny, C.; Prevarskaya, N. Calcium-permeable ion channels in control of autophagy and cancer. Front. Physiol. 2013, 4, 272.
104. Tooze, S.A. Current views on the source of the autophagosome membrane. Essays Biochem. 2013, 55, 29-38.